Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Leah LawrenceTriple-Negative Breast Cancer | April 15, 2025

Sacituzimab govitecan showed modest CNS activity in pretreated HER2-negative metastatic breast cancer with brain metastases.

De-Escalation of Neoadjuvant Chemoimmunotherapy May Be Feasible Option

Leah LawrenceTriple-Negative Breast Cancer | April 9, 2025

Shorter chemoimmunotherapy shows promise in early TNBC, with higher pCR in PD-L1+ or TIL-high patients, Neo-N trial finds.

Study Shows No Clinical Benefit Observed With Atezolizumab as Adjunctive Therapy for Triple Negative Breast Cancer

Yvette C. TerrieTriple-Negative Breast Cancer | April 8, 2025

Adding atezolizumab to chemotherapy did not result in clinical benefit in patients with triple-negative breast cancer.

Imlunestrant is a Viable Second-Line Option for Advanced HR-Positive, HER2-Negative Breast Cancer

Leah LawrenceHR Breast Cancer | April 7, 2025

Imlunestrant with or without abemaciclib improved PFS in ER+/HER2- advanced breast cancer post-endocrine therapy.

Study Shows That Black Patients With Metastatic Breast Cancer Tend to Experience Higher Mortality Rates Than White Patients

Yvette C. TerrieBreast Cancer News | April 6, 2025

Study finds somatic differences and lower PI3K inhibitor use in Black vs White patients with metastatic breast cancer.

PENELOPE-B Final Analysis: Palbociclib Shows No Survival Benefit in High-Risk HR+/HER2- Breast Cancer

Brandon TwyfordHR Breast Cancer | April 5, 2025

Final results from the PENELOPE-B trial show palbociclib did not improve survival in high-risk HR+/HER2– breast cancer.

EU Approves Enhertu for HR-Positive, HER2-Low, HER2-Ultralow Metastatic Breast Cancer Following Endocrine Therapy

Brandon TwyfordHER2 Breast Cancer | April 4, 2025

Enhertu approved in the EU for HR+, HER2-low, -ultralow metastatic breast cancer, showing PFS benefit over chemotherapy.

Interim SERENA-6 Data: Camizestrant Significantly Improves PFS in First-Line HR+/HER2- Advanced Breast Cancer With ESR1 Mutations

Yvette C. TerrieHR Breast Cancer | April 4, 2025

Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations.

Evaluating HER2-Low in Metastatic Breast Cancer: Cytological Insights Into Proliferation and Survival

Brianna GrahamHER2 Breast Cancer | April 3, 2025

Cytology provides new insights into HER2-low metastatic breast cancer, revealing proliferative features and survival trends.

Improving HER2-Low Diagnosis in Metastatic Breast Cancer: Validating a Scoring System to Enhance Pathologist Precision

Brianna GrahamHER2 Breast Cancer | April 2, 2025

A new study validates a HER2-low–focused scoring system to improve diagnostic accuracy in metastatic breast cancer.

Expert Interviews on Oncology

DocWire News delivers the latest medical industry news, giving health care professionals the curated content most relevant to their fields and practices.

Get the latest medical updates and insights straight to your inbox.

Section Editor

Dr. Sadie Dobrozsi, EvolentHematologist/oncologist and Medical Director, Evolent